A new study shows that combining laser treatment with immunotherapy significantly improves survival rates in patients with ...

Adding a minimally invasive laser procedure to immunotherapy achieved dramatically improved survival in a small study of ...

MRK's Keytruda posted $31.7B in 2025 sales. Can new approvals, ongoing studies and a revamped structure keep oncology growth strong through 2026?

Merck said on Monday that it will split its human-health operations into two separate divisions, a move designed to sharpen focus across its portfolio and ensure smoother launches of new medicines.

New KEYTRUDA indications are expected to preserve Merck's top line, significantly aided by the high single-digit Animal Health/Livestock and the triple-digit Winrevair revenue growth in FY2025.

As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompanying test to identify patients who can best benefit from the drug. The test, PD-L1 ...

KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...

For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.

Add Yahoo as a preferred source to see more of our stories on Google. Moderna and MSD's mRNA cancer vaccine A combination of Moderna and MSD's personalised cancer vaccine, intismeran autogene, and MSD ...